Genetics of Psoriasis and Pharmacogenetics of Biological Drugs

Abstract EN

Psoriasis is a chronic inflammatory disease of the skin.

The causes of psoriasis are unknown, although family and twin studies have shown genetic factors to play a key role in its development.

The many genes associated with psoriasis and the immune response include TNFα, IL23, and IL12.

Advances in knowledge of the pathogenesis of psoriasis have enabled the development of new drugs that target cytokines (e.g., etanercept, adalimumab, and infliximab, which target TNFα, and ustekinumab, which targets the p40 subunit of IL23 and IL12).

These drugs have improved the safety and efficacy of treatment in comparison with previous therapies.

However, not all patients respond equally to treatment, possibly owing to interindividual genetic variability.

In this review, we describe the genes associated with psoriasis and the immune response, the biological drugs used to treat chronic severe plaque psoriasis, new drugs in phase II and III trials, and current knowledge on the implications of pharmacogenomics in predicting response to these treatments.